Vivek Subbiah: Mark your calendars if you are attending the ESMO MAP23 meeting in Paris, France this week, Oct 4-6.

Quoting Vivek Subbiah, Chief of Early-Phase Drug Development at the  Sarah Cannon Research Institute, on X/Twitter:

“ANNOUNCEMENT: Mark your calendars if you are attending the ESMO MAP23 meeting in Paris, France this week, Oct 4-6. Super thrilled to co-Chair a very important session on Tumor Agnostic and Precision Medicine with Dr. Francesco Pignatti, Head of Oncology, Haematology, Diagnostics – Safety and Efficacy Sector at European Medicines Agency (EMA).
What are the current roadblocks to histology agnostic biomarker driven approvals?
Hear directly from speakers from US FDA, EMA and from the patient perspective.”

For more information click here.
Source: Vivek Subbiah/Twitter.